Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer

The majority of patients with HER2-overexpressing metastatic breast cancer who initially respond to the HER2-targeted antibody trastuzumab show disease progression within 1 year. The identification of novel agents that effectively inhibit survival of cancer cells that have progressed on trastuzumab...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular cancer therapeutics Vol. 7; no. 7; p. 1900
Main Authors:	Rowe, Danica L, Ozbay, Tuba, Bender, Laura M, Nahta, Rita
Format:	Journal Article
Language:	English
Published:	United States 01.07.2008
Subjects:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Antineoplastic Agents - pharmacology Breast Neoplasms - pathology Cell Death - drug effects Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Drug Resistance, Neoplasm - drug effects Drug Screening Assays, Antitumor Drug Synergism Humans Insulin-Like Growth Factor I - metabolism Masoprocol - pharmacology Receptor, ErbB-2 - antagonists & inhibitors Receptor, IGF Type 1 - antagonists & inhibitors Signal Transduction - drug effects Trastuzumab Treatment Outcome
ISSN:	1535-7163
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!